Shanghai Desano Biopharmaceutical Co., Ltd, a leading biopharmaceutical company based in China, has entered into a strategic partnership with Chongqing Kangfude Pharmaceutical Co., Ltd to establish a state-of-the-art peptide drug API and preparation production base in Chongqing. The collaboration involves an investment of RMB 120 million (USD 16.5 million) by Desano into Kangfude, which will be directed towards the construction of an integrated industrial chain for peptide manufacturing.
The new peptide drug production workshop will adhere to the Good Manufacturing Practice (GMP) standards of China, the US, and the EU. Upon completion, the facility is expected to manufacture a range of 5-8 peptide products, including Semaglutide and Tirzepatide, at a large scale. Semaglutide is a GLP-1 analog used for the treatment of type 2 diabetes and obesity, while Tirzepatide is a dual GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction .- Flcube.com
